Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy

a systematic review and meta-analysis

Benjamin A. Gartrell, Jian Ying, Shanthi Sivendran, Kenneth M. Boucher, Toni K. Choueiri, Guru Sonpavde, William K. Oh, Neeraj Agarwal, Matthew D. Galsky

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Mammalian target of rapamycin (mTOR) inhibitors have gained regulatory approval for use in several cancer types. Pulmonary adverse events associated with mTOR inhibitors are well recognized but their frequency has varied considerably among trials. PubMed and ASCO abstracts were searched to identify clinical trials of mTOR inhibitors in solid tumors. Twenty-two eligible trials on which 4,242 patients were treated met the criteria for inclusion in this systematic review and meta-analysis. Adverse event data were extracted and used to determine the incidence rate and incidence rate ratio for pneumonitis, dyspnea, and cough. The incidence rate of any grade pneumonitis in patients with solid tumors treated with mTOR inhibitors was 0.11 (95% confidence interval (CI), 0.06-0.17) per patient, while the incidence of grade 3-4 pneumonitis was 0.03 (95% CI, 0.01-0.04) per patient. The incidence rate ratio (IRR) of any grade pneumonitis with mTOR inhibitors relative to controls was 19.0 (95% CI, 6.5-55.4), and for grade 3-4 pneumonitis was 8.0 (95% CI, 2.6-24.1). The incidence rate for any grade and grade 3-4 cough was 0.23 (95% CI, 0.20-0.27) per patient and 0.01 (95% CI, 0.00-0.01) per patient, respectively. The incidence rate for any grade and grade 3-4 dyspnea was 0.15 (95% CI, 0.10-0.21) per patient and 0.03 (95% CI, 0.02-0.04) per patient, respectively. Compared to control, treatment with mTOR inhibitors were associated with a significant increase in any grade cough [IRR = 1.9 (95% CI, 1.6-2.4)] and grade 3-4 dyspnea [IRR = 2.0 (95% CI, 1.2-3.3)]. This study provides an estimation of the risk of pulmonary adverse events in solid tumor patients treated with mTOR inhibitors. While pulmonary adverse events are relatively common with mTOR inhibitors, most are low grade and asymptomatic.

Original languageEnglish (US)
Pages (from-to)195-204
Number of pages10
JournalTargeted Oncology
Volume9
Issue number3
DOIs
StatePublished - Sep 1 2014

Fingerprint

Sirolimus
Meta-Analysis
Confidence Intervals
Lung
Incidence
Neoplasms
Pneumonia
Cough
Dyspnea
Therapeutics
PubMed
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy : a systematic review and meta-analysis. / Gartrell, Benjamin A.; Ying, Jian; Sivendran, Shanthi; Boucher, Kenneth M.; Choueiri, Toni K.; Sonpavde, Guru; Oh, William K.; Agarwal, Neeraj; Galsky, Matthew D.

In: Targeted Oncology, Vol. 9, No. 3, 01.09.2014, p. 195-204.

Research output: Contribution to journalArticle

Gartrell, BA, Ying, J, Sivendran, S, Boucher, KM, Choueiri, TK, Sonpavde, G, Oh, WK, Agarwal, N & Galsky, MD 2014, 'Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis', Targeted Oncology, vol. 9, no. 3, pp. 195-204. https://doi.org/10.1007/s11523-013-0289-2
Gartrell, Benjamin A. ; Ying, Jian ; Sivendran, Shanthi ; Boucher, Kenneth M. ; Choueiri, Toni K. ; Sonpavde, Guru ; Oh, William K. ; Agarwal, Neeraj ; Galsky, Matthew D. / Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy : a systematic review and meta-analysis. In: Targeted Oncology. 2014 ; Vol. 9, No. 3. pp. 195-204.
@article{2b5b88e554094ff78ba82f31dc4744d4,
title = "Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis",
abstract = "Mammalian target of rapamycin (mTOR) inhibitors have gained regulatory approval for use in several cancer types. Pulmonary adverse events associated with mTOR inhibitors are well recognized but their frequency has varied considerably among trials. PubMed and ASCO abstracts were searched to identify clinical trials of mTOR inhibitors in solid tumors. Twenty-two eligible trials on which 4,242 patients were treated met the criteria for inclusion in this systematic review and meta-analysis. Adverse event data were extracted and used to determine the incidence rate and incidence rate ratio for pneumonitis, dyspnea, and cough. The incidence rate of any grade pneumonitis in patients with solid tumors treated with mTOR inhibitors was 0.11 (95{\%} confidence interval (CI), 0.06-0.17) per patient, while the incidence of grade 3-4 pneumonitis was 0.03 (95{\%} CI, 0.01-0.04) per patient. The incidence rate ratio (IRR) of any grade pneumonitis with mTOR inhibitors relative to controls was 19.0 (95{\%} CI, 6.5-55.4), and for grade 3-4 pneumonitis was 8.0 (95{\%} CI, 2.6-24.1). The incidence rate for any grade and grade 3-4 cough was 0.23 (95{\%} CI, 0.20-0.27) per patient and 0.01 (95{\%} CI, 0.00-0.01) per patient, respectively. The incidence rate for any grade and grade 3-4 dyspnea was 0.15 (95{\%} CI, 0.10-0.21) per patient and 0.03 (95{\%} CI, 0.02-0.04) per patient, respectively. Compared to control, treatment with mTOR inhibitors were associated with a significant increase in any grade cough [IRR = 1.9 (95{\%} CI, 1.6-2.4)] and grade 3-4 dyspnea [IRR = 2.0 (95{\%} CI, 1.2-3.3)]. This study provides an estimation of the risk of pulmonary adverse events in solid tumor patients treated with mTOR inhibitors. While pulmonary adverse events are relatively common with mTOR inhibitors, most are low grade and asymptomatic.",
author = "Gartrell, {Benjamin A.} and Jian Ying and Shanthi Sivendran and Boucher, {Kenneth M.} and Choueiri, {Toni K.} and Guru Sonpavde and Oh, {William K.} and Neeraj Agarwal and Galsky, {Matthew D.}",
year = "2014",
month = "9",
day = "1",
doi = "10.1007/s11523-013-0289-2",
language = "English (US)",
volume = "9",
pages = "195--204",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "3",

}

TY - JOUR

T1 - Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy

T2 - a systematic review and meta-analysis

AU - Gartrell, Benjamin A.

AU - Ying, Jian

AU - Sivendran, Shanthi

AU - Boucher, Kenneth M.

AU - Choueiri, Toni K.

AU - Sonpavde, Guru

AU - Oh, William K.

AU - Agarwal, Neeraj

AU - Galsky, Matthew D.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Mammalian target of rapamycin (mTOR) inhibitors have gained regulatory approval for use in several cancer types. Pulmonary adverse events associated with mTOR inhibitors are well recognized but their frequency has varied considerably among trials. PubMed and ASCO abstracts were searched to identify clinical trials of mTOR inhibitors in solid tumors. Twenty-two eligible trials on which 4,242 patients were treated met the criteria for inclusion in this systematic review and meta-analysis. Adverse event data were extracted and used to determine the incidence rate and incidence rate ratio for pneumonitis, dyspnea, and cough. The incidence rate of any grade pneumonitis in patients with solid tumors treated with mTOR inhibitors was 0.11 (95% confidence interval (CI), 0.06-0.17) per patient, while the incidence of grade 3-4 pneumonitis was 0.03 (95% CI, 0.01-0.04) per patient. The incidence rate ratio (IRR) of any grade pneumonitis with mTOR inhibitors relative to controls was 19.0 (95% CI, 6.5-55.4), and for grade 3-4 pneumonitis was 8.0 (95% CI, 2.6-24.1). The incidence rate for any grade and grade 3-4 cough was 0.23 (95% CI, 0.20-0.27) per patient and 0.01 (95% CI, 0.00-0.01) per patient, respectively. The incidence rate for any grade and grade 3-4 dyspnea was 0.15 (95% CI, 0.10-0.21) per patient and 0.03 (95% CI, 0.02-0.04) per patient, respectively. Compared to control, treatment with mTOR inhibitors were associated with a significant increase in any grade cough [IRR = 1.9 (95% CI, 1.6-2.4)] and grade 3-4 dyspnea [IRR = 2.0 (95% CI, 1.2-3.3)]. This study provides an estimation of the risk of pulmonary adverse events in solid tumor patients treated with mTOR inhibitors. While pulmonary adverse events are relatively common with mTOR inhibitors, most are low grade and asymptomatic.

AB - Mammalian target of rapamycin (mTOR) inhibitors have gained regulatory approval for use in several cancer types. Pulmonary adverse events associated with mTOR inhibitors are well recognized but their frequency has varied considerably among trials. PubMed and ASCO abstracts were searched to identify clinical trials of mTOR inhibitors in solid tumors. Twenty-two eligible trials on which 4,242 patients were treated met the criteria for inclusion in this systematic review and meta-analysis. Adverse event data were extracted and used to determine the incidence rate and incidence rate ratio for pneumonitis, dyspnea, and cough. The incidence rate of any grade pneumonitis in patients with solid tumors treated with mTOR inhibitors was 0.11 (95% confidence interval (CI), 0.06-0.17) per patient, while the incidence of grade 3-4 pneumonitis was 0.03 (95% CI, 0.01-0.04) per patient. The incidence rate ratio (IRR) of any grade pneumonitis with mTOR inhibitors relative to controls was 19.0 (95% CI, 6.5-55.4), and for grade 3-4 pneumonitis was 8.0 (95% CI, 2.6-24.1). The incidence rate for any grade and grade 3-4 cough was 0.23 (95% CI, 0.20-0.27) per patient and 0.01 (95% CI, 0.00-0.01) per patient, respectively. The incidence rate for any grade and grade 3-4 dyspnea was 0.15 (95% CI, 0.10-0.21) per patient and 0.03 (95% CI, 0.02-0.04) per patient, respectively. Compared to control, treatment with mTOR inhibitors were associated with a significant increase in any grade cough [IRR = 1.9 (95% CI, 1.6-2.4)] and grade 3-4 dyspnea [IRR = 2.0 (95% CI, 1.2-3.3)]. This study provides an estimation of the risk of pulmonary adverse events in solid tumor patients treated with mTOR inhibitors. While pulmonary adverse events are relatively common with mTOR inhibitors, most are low grade and asymptomatic.

UR - http://www.scopus.com/inward/record.url?scp=84929941715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929941715&partnerID=8YFLogxK

U2 - 10.1007/s11523-013-0289-2

DO - 10.1007/s11523-013-0289-2

M3 - Article

VL - 9

SP - 195

EP - 204

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 3

ER -